DekaBank Deutsche Girozentrale
AEGR

DekaBank Deutsche Girozentrale’s Aegerion Pharmaceuticals AEGR Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17,500
Closed -$68K – 1086
2016
Q1 		$68K Buy
17,500
+2,750
+19% +$17K ﹤0.01% 1005
2015
Q4 		$151K Buy
14,750
+400
+3% +$4.82K ﹤0.01% 914
2015
Q3 		$195K Buy
14,350
+500
+4% +$8.9K ﹤0.01% 880
2015
Q2 		$263K Buy
13,850
+500
+4% +$10.8K ﹤0.01% 822
2015
Q1 		$349K Sell
13,350
-2,500
-16% -$63.6K ﹤0.01% 795
2014
Q4 		$336K Sell
15,850
-1,400
-8% -$35.3K ﹤0.01% 776
2014
Q3 		$576K Buy
17,250
+300
+2% +$9.31K 0.01% 627
2014
Q2 		$544K Sell
16,950
-1,500
-8% -$55.9K 0.01% 588
2014
Q1 		$852K Buy
18,450
+1,900
+11% +$111K 0.01% 497
2013
Q4 		$1.19M Buy
16,550
+450
+3% +$34.4K 0.02% 402
2013
Q3 		$1.38M Buy
16,100
+650
+4% +$55.1K 0.02% 372
2013
Q2 		$1.03M Buy
+15,450
New +$820K 0.02% 368

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DekaBank Deutsche Girozentrale's AEGR Position: Q2 2016 in Review

DekaBank Deutsche Girozentrale sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 17,500 shares — an estimated $68K sold.

DekaBank Deutsche Girozentrale first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $1.38M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • DekaBank Deutsche Girozentrale reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 17,500 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $68K.
  • DekaBank Deutsche Girozentrale first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • DekaBank Deutsche Girozentrale's Aegerion Pharmaceuticals position peaked at $1.38M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2016, filed 4 Aug 2016.